Cybin (CYBN) vs. Its Peers Financial Contrast
by Teresa Graham · The Cerbat GemCybin (NYSE:CYBN – Get Free Report) is one of 443 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Cybin to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Profitability
This table compares Cybin and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cybin | N/A | -109.05% | -97.85% |
| Cybin Competitors | -8,581.07% | -107.97% | -23.29% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Cybin and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cybin | 0 | 0 | 3 | 0 | 3.00 |
| Cybin Competitors | 734 | 2177 | 5081 | 56 | 2.55 |
Cybin presently has a consensus price target of $50.50, indicating a potential upside of 445.95%. As a group, “Biotechnology” companies have a potential upside of 10.12%. Given Cybin’s stronger consensus rating and higher possible upside, research analysts clearly believe Cybin is more favorable than its rivals.
Volatility & Risk
Cybin has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Cybin’s rivals have a beta of 1.26, meaning that their average stock price is 26% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cybin and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cybin | N/A | -$35.93 million | -46.25 |
| Cybin Competitors | $148.01 million | -$13.29 million | -17.59 |
Cybin’s rivals have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
17.9% of Cybin shares are owned by institutional investors. Comparatively, 29.2% of shares of all “Biotechnology” companies are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 25.7% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Cybin rivals beat Cybin on 9 of the 13 factors compared.
About Cybin
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.